GENinCode has a significant addressable market in the risk assessment and diagnosis of cardiovascular disease. There are already initial sales for the diagnostic products, but the company needs to show that it can build up demand in other markets, particularly the US.
The autumn should bring news about progress with FDA approval. That could boost the share price.
The shares did not get off to a good start and the price has fallen to 36.7p (36.4p/37p). That is despite positive news about clinical results for Thrombo inCode, a diagnostic for inherited thrombophilia and venous thromboembolism risk assessment.
The share price appears to be settling down at around 37p after four trading days. That means the company is valued at less than the cash invested in the technology with the mo...